内容紹介
悪性腫瘍領域でのPET/CTの利点は、生検や手術に比べて低侵襲で繰り返し検査可能であること、解剖学的な情報や病変内部の性質についての情報も得られるため初期診断だけでなく治療効果判定や腫瘍内のheterogeneityの描出が可能であることが挙げられる。現在臨床で繁用されている18F-Fluorodeoxyglucoseだけでなく、今後さらなるバイオマーカー開発により各種トレーサーの臨床開発が進むことでPET/CTの一層の発展が期待される。
Most of the current biomarker approaches require invasive methods, such as a biopsy or surgical resection, to obtain tissue specimens for analysis. Although these methods are valuable, they lack information about localization of the biopsied tissue that could delineate heterogeneity within the lesions. PET/CT can provide the means for non invasive and repetitive assessments with biochemical, functional, genetic, molecular, and signaling processes information. It can greatly improve our understanding of the mechanisms of cancer development, progression, and individual differences.
目次
Most of the current biomarker approaches require invasive methods, such as a biopsy or surgical resection, to obtain tissue specimens for analysis. Although these methods are valuable, they lack information about localization of the biopsied tissue that could delineate heterogeneity within the lesions. PET/CT can provide the means for non invasive and repetitive assessments with biochemical, functional, genetic, molecular, and signaling processes information. It can greatly improve our understanding of the mechanisms of cancer development, progression, and individual differences.